Navigation Links
First polymer solar-thermal device heats home, saves money
Date:4/4/2011

heat pump, for example, to transfer the heat inside a home.

Unlike the flat solar cells used today, the curve of the tubes inside the new device allows for the collection of both visible light and infrared heat from nearly sunrise to sunset. This means it provides power for a much greater part of the day than does a normal solar cell.

Because of the general structure and the ability to capture light at oblique angles, this is also the first solar-thermal device that can be truly building-integrated it can be made to look nearly identical to roofing tiles used today.

Tests of the solar-thermal device have shown 30 percent efficiency in converting solar energy to power. By comparison, a standard solar cell with a polymer absorber has shown no greater than 8 percent conversion efficiency.

The research team will build the first square-meter-size solar-thermal cell this summer, a key step in getting the technology ready for market.


'/>"/>

Contact: Ellen Sterner Sedeno
sternersedeno@sbcglobal.net
336-758-5237
Wake Forest University
Source:Eurekalert

Page: 1 2

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. MEDRAD Installs First Intego(TM) PET Infusion System
3. Pioneering IVF Technique Produces Region's First Pregnancy
4. Immtech Reports Fiscal First Quarter 2009 Results
5. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
6. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
7. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
8. Video: CSL Behring Provides $1.2M Grant for Worlds First Study of Postpartum Women with VWD, Common Bleeding Disorder
9. Natures Premium(R) Brand First Fresh Pork in North America to Carry DNA TraceBack(R) Seal of Authenticity
10. Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging Market of Brazil
11. States First Single Incision Robotic Kidney Removal Performed at Henry Ford Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  Prima Biomed Ltd. ... that is striving to become a leader in the ... recently announced that the final CVac data from the ... a clear trend for a clinically meaningful improvement in ... second remission patients. In the group of ...
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... 2015 W. R. Grace & ... in Worms, Germany has received good manufacturing practice ... the International Pharmaceutical Excipient Council (IPEC) Foundation. ... its SYLOID® FP brand of pharmaceutical grade excipient ... the Curtis Bay, Maryland (USA) and Sorocaba, Brazil ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... March 28, 2011 DRIVE4COPD, the nation,s single largest ... named PRWeek,s Healthcare Campaign of the Year ... the most prestigious honors in the public relations industry, ... and education teams.  Boehringer Ingelheim Pharmaceuticals, Inc. is the ...
... March 28, 2011 Clinicians now have a new tool ... and HSV2) -- one of the most common sexually transmitted ... segment of BD (Becton, Dickinson and Company), announced today that ... for the first fully automated molecular tests to detect and ...
... March 28, 2011 BioMarin Pharmaceutical Inc. ... that Jean-Jacques Bienaime, Chief Executive Officer of ... webcast on Thursday, April 28, at 5:00 ... financial results.U.S. / Canada Dial-in Number:  888.396.2386International ...
Cached Biology Technology:DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 2DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 3DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011 4BD Diagnostics Receives FDA Clearance for First Fully Automated Molecular Assays for HSV1 and HSV2 from Clinician-Collected External Anogenital Lesion Specimens 2BioMarin to Host First Quarter 2011 Financial Results Conference Call and Webcast on Thursday, April 28 at 5:00 p.m. ET 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015 According to ... Biometrics Market Forecast & Opportunities, 2020", the global biometrics ... around 14% till 2020. The biometrics market is ... implementation and review of biometric management systems. The ... products with greater efficiency, are resulting in increasing ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2Synaptics to Report Third Quarter Results on April 23 2
... November 9, 2010 The Ontario Genomics Institute (OGI) ... at St. Joan of Arc Catholic Secondary School (Mississauga, ... Prize. The annual prize recognizes the Ontario secondary ... preparing Ontario,s students for their future roles: perhaps ...
... University of Toronto have shown that the nature of ... individual,s sensitivity to physical pain. The discovery could ... general well-being of an individual on a daily basis. ... have demonstrated the impact of inadequate social connectedness on ...
... activity of nerve cells in a songbird,s brain as it ... in the Department of Physics at Penn State University and ... string together sets of syllables -- or notes in a ... brain learns language and produces speech. The research will be ...
Cached Biology News:Mississauga teacher awarded prize for excellence in teaching genomics 2Mississauga teacher awarded prize for excellence in teaching genomics 3Psychologists identify influence of social interaction on sensitivity to physical pain 2Scientists discover how the songbird's brain controls timing during singing 2
... a special preparation of bovine pancreatic DNase I ... of DNA molecules. In the presence of Mn2+ ... strand breaks at random sites in DNA. The ... controlled by the enzyme concentration and incubation time. ...
... potent TURBO DNase (patent pending) in the TURBO ... DNA removal capabilities. TURBO DNase is a recombinant, ... more efficient than wild type DNase I in ... DNase binds DNA substrates 6-fold more tightly than ...
... IEC Centra CL3 series is designed ... research and clinical applications at a ... package includes quick connect rotors and ... yet intuitive interface allows you to ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: